CD8A and nonpapillary renal cell carcinoma: Given that CD8 T cells have been recognized to contribute to antitumor immunity in patients with metastatic ccRCC undergoing nivolumab treatment [20] and that the high M2 macrophage subtype is associated with worse prognosis in patients with ccRCC [21], we believe that these different immune cell characteristics may explain why clinical outcomes differed between patients with and without SF loss in the present study.